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Cancer, like many common disorders, has a complex etiology, often with a strong genetic component and with
multiple environmental factors contributing to susceptibility. A considerable number of genomic variants have been
previously reported to be causative of, or associated with, an increased risk for various types of cancer. Here, we
adopted a next-generation sequencing approach in 11 members of two families of Greek descent to identify all
genomic variants with the potential to predispose family members to cancer. Cross-comparison with data from
the Human Gene Mutation Database identified a total of 571 variants, from which 47 % were disease-associated
polymorphisms, 26 % disease-associated polymorphisms with additional supporting functional evidence, 19 %
functional polymorphisms with in vitro/laboratory or in vivo supporting evidence but no known disease association,
4 % putative disease-causing mutations but with some residual doubt as to their pathological significance, and 3 %
disease-causing mutations. Subsequent analysis, focused on the latter variant class most likely to be involved in cancer
predisposition, revealed two variants of prime interest, namely MSH2 c.2732T>A (p.L911R) and BRCA1 c.2955delC, the
first of which is novel. KMT2D c.13895delC and c.1940C>A variants are additionally reported as incidental findings. The
next-generation sequencing-based family genomics approach described herein has the potential to be applied to
other types of complex genetic disorder in order to identify variants of potential pathological significance.
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Cancer results from a multi-step cascade of somatic
events involving the accumulation of both genetic and
epigenetic changes at various genomic loci, under the in-
fluence of a variety of different environmental factors
[1–5]. Single point mutations, small insertions/deletions,
translocations, gene fusions, copy number changes, and
loss of heterozygosity represent some of the somatic* Correspondence: gpatrinos@upatras.gr
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creativecommons.org/publicdomain/zero/1.0/alterations frequently encountered in cancer [6] and
which can lead to the increased expression of oncogenes
or to the silencing of tumor suppressor genes. Genome-
wide association studies (GWASs) have also identified
genomic regions that appear to be associated with in-
creased cancer risk [7–9]. It is to be expected that an
improved knowledge of the genomic variants that pre-
dispose to tumor initiation, development, and progres-
sion will be advantageous in the context of informing
treatment regimens. Numerous studies have been per-
formed in an attempt to shed light on the complexity
(and inter-individual variability) of the cancer genome
and to examine the relationship between the possession
of specific genomic variants and tumorigenesis [10, 11],
often with ambiguous results.ess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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provided unprecedented opportunities to decipher the
cancer genome and to dissect the molecular etiology of
cancer predisposition. This has been the primary goal of
the International Cancer Genome Consortium (ICGC),
following the initiatives of the Human Genome Project
and the HapMap Consortium [12]. The comprehensive
listings of genomic abnormalities (somatic mutations,
abnormal gene expression, epigenetic effects) detected in
tumors from 50 cancer types and/or subtypes of clinical
and societal importance are being made available to the
entire research community with minimal restrictions
(http://www.icgc.org/icgc). In this context, the Catalogue
of Somatic Mutations in Cancer (COSMIC; http://cancer.
sanger.ac.uk/cancergenome/projects/cosmic) stores and
displays our current knowledge of somatic mutations
detected in human cancers, including information on
publications and most notably, tissue samples (i.e., benign
neoplasms, in situ and invasive tumors, recurrences,
metastases) and cancer cell lines. In 2004, the Cancer
Gene Census (http://cancer.sanger.ac.uk/cancergenome/
projects/census) indicated that mutations in more than
1 % of genes may contribute to human cancer [13]. A total
of 547 entries are currently reported, of which 90 % refer
to somatic mutations in cancer, 20 % correspond to germ-
line mutations that predispose to cancer, whereas 10 %
refer to both somatic and germline mutations.
Genetic susceptibility to cancer is conferred both by
inherited (germline) and tumor-specific (somatic) vari-
ants and as such, it is evident in most individuals, not
just in those individuals with a personal or family history
of cancer. Although the deleterious alleles of cancer risk
genes are generally not highly penetrant, the presence of
genetic susceptibility variants at multiple loci is generally
assumed to increase an individual’s overall risk of cancer.
It should be noted that, even in the case of highly pene-
trant cancer predisposition genes, such as BRCA1 and
BRCA2, population-based studies have revealed that
about half of all heterozygous mutation carriers with in-
cident cancers lack a family history of breast or ovarian
cancer [14]. Further, individuals with no obvious indica-
tion of cancer risk from family history may nevertheless
be at an increased risk of developing cancer [15]. NGS
technologies have potentiated the analysis of whole ge-
nomes as a means to obtain a full picture of individual
variomes [16]. Once whole genome and/or whole exome
sequencing begins to take hold in routine clinical medi-
cine, developing an understanding of the role of the de-
tected sequence variations in guiding diagnostics and
arriving at prognoses will be of paramount importance
to the clinician, especially in the case of multifactorial
disorders and cancer, where early detection of novel
causative variants can be crucial for early disease diagno-
sis and health management. In the context of cancer,data interpretation will require an understanding of the
heritable variation present in cancer risk-associated
genes in healthy individuals. Currently, this knowledge is
largely lacking.
Here, we propose a multi-step next-generation sequencing-
based family genomics approach, piloted in 11 members
of two families of Greek descent with no history of can-
cer, to identify genomic variants, particularly novel vari-
ants, that might predispose to various types of cancer.
Such information could help in the assessment of person-
alized cancer-susceptibility risk from genome sequence
data [17].
Materials and methods
Case selection, DNA isolation, and whole genome
sequencing
Eleven members of two unrelated families of Greek descent
were recruited for this study (Fig. 1). All individuals con-
sented to participate. A family-based design was employed
rather than a population-based design, as the former is
generally considered to be robust against population ad-
mixture and stratification and may yield both within- and
between-family information [18]. None of the individuals
tested had a family history of cancer (germline risk vari-
ants would not be anticipated as they are quite infrequent,
although they cannot altogether be excluded). We aimed
to identify cancer-susceptibility variants of low penetrance
in these apparently healthy individuals, information that
could help in the assessment of personalized cancer-
susceptibility risk from genome sequence data. It was
hoped that the application of the NGS approach might
lead to the identification of novel cancer-susceptibility var-
iants. Informed consent was obtained from all individuals
who took part in this study.
Genomic DNA isolation was performed from saliva
samples using the Oragene collection kit (DNA Geno-
tek, Canada). Whole genome sequencing was performed
using the proprietary DNA nanoball resequencing tech-
nology of Complete Genomics [19]. DNA sequencing
coverage was 110×.
Bioinformatics and in silico analyses
All variants were filtered according to the analysis re-
quired, using custom scripts and Complete Genomics
Analysis Tools [CGA™ Tools]. Only high-quality call
variants were included in the analysis (>93 %). Genomes
were aligned with the hg19 reference genome and sub-
sequently compared against the Human Gene Mutation
Database, Professional version (HGMD v.2014.4; http://
www.hgmd.org) records with respect to previously known
variants in cancer predisposition genes. Subsequently,
a non-redundant list of variants was generated from
the 11 human genome sequences and subjected to
text mining, using the following keywords: “Cancer,”
Fig. 1 Pedigrees of the two families (a, b) of Greek descent whose genomes were analyzed
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oma,” “Lymphoma,” “Leukemia,” “Glioma,” and “Glio-
blastoma.” Novel variants in genes that had previously
been related to cancer predisposition were annotated
with Annovar in Galaxy [20] and compared with NCBI
dbSNP build 137 (http://www.ncbi.nlm.nih.gov/projects/SNP/
snp_summary.cgi), 69 reference genomes from Complete
Genomes (http://www.completegenomics.com/publicdata/
69Genomes/), COSMIC v68 (http://cancer.sanger.ac.uk/
cosmic/version68), and GWAS studies (http://www.genome.
gov/gwastudies) to determine their novelty or otherwise.
To obtain a list of variants of potential functional sig-
nificance, we employed protein variation effect analyzer
(PROVEAN) v1.1.3 (PROVEAN human genome variants
tool) that provides both scale-invariant feature transform
(SIFT) [21] and PROVEAN [22] predictions for a given
list of human genome variants as well as accessory infor-
mation (dbSNP rs IDs, gene description, PFAM domain,
GO terms, etc.). PROVEAN is able to make predictions
for any type of protein sequence alteration, including sin-
gle or multiple amino acid substitutions, deletions, and
insertions [23]. In addition, we used CRAVAT (Cancer-
Related Analysis of Variants Toolkit), a tool more specific-
ally tailored to a cancer variant application, to facilitate
the high-throughput assessment and prioritization of
genes important for cancer tumorigenesis [24].Downstream molecular analysis
Selected novel variants were subsequently analyzed using
a polymerase chain reaction (PCR)-based conventional
Sanger resequencing approach and validated in a pool of
ethnically matched 60 control samples to determine
whether or not they constituted frequent variants.
Results
Next-generation sequencing-based family genomics
The family genomics approach adopted herein is depicted
in Fig. 2. Eleven members from two unrelated Greek fam-
ilies had their genomes sequenced. None of the individuals
from the families selected had any history of cancer, as in-
dicated by the participants. Our family-based approach
was adopted in order to identify known cancer risk vari-
ants as well as novel variants of low penetrance—although
highly penetrant genes cannot be excluded—in healthy in-
dividuals, information that could help in the assessment of
personalized cancer-susceptibility risk from genome se-
quence data.
A list of 571 non-redundant genomic variants that
might predispose family members to cancer was identified
after cross-comparison with HGMD entries (Additional
file 1: Table S1) and further categorized by genome/family
member on the basis of the text mining terms used. To
further address individual cancer risk, clinical impact data
Fig. 2 Outline of the concept of the family genomics approach implemented in this study
Fig. 3 Summary of the genomic variants identified, grouped per
variant classes in the HGMD database. HGMD variant classes were as
follows: DP disease-associated polymorphisms, DFP disease-
associated polymorphisms with additional supporting functional evi-
dence, FP functional polymorphisms with in vitro/laboratory or
in vivo supporting evidence but no known disease association DM
disease-causing mutations, DM? putative disease-causing mutations
but where there is some residual doubt as to
pathological significance
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lele frequencies (Complete Genomics 69 diversity file),
1000 Genomes Project data as well as the input of COS-
MIC v68.
Analysis of 11 genomes reveals a large number of
potential cancer predisposition variants
Cross-comparison with data from the Human Gene Mu-
tation Database identified a total of 571 heritable variants
that had previously been reported to be associated with
cancer predisposition (Additional file 1: Table S1). Taking
into account the variant classes included in the HGMD
dataset, the distribution of our 571 variants was 47 % DP
(disease-associated polymorphisms), 26 % DFP (disease-
associated polymorphisms with additional supporting
functional evidence), 19 % FP (functional polymorphisms
with in vitro/laboratory or in vivo supporting evidence but
no known disease association), 4 % DM? (putative disease-
causing mutations but where there is some residual doubt
as to pathological significance), and 3 % DM (disease-
causing mutations) (Fig. 3). Subsequent analysis focused
on the DMs as the variant class most likely to be involved
in cancer predisposition (Table 1). Cancer predisposition
to various cancer types was revealed including brain,
head and neck, bladder, breast, lung, gastric, prostate,
colorectal, ovarian, thyroid, oral, hereditary non-polyposis
colorectal cancer (HNPCC), esophageal, upper aerodiges-
tive tract, pancreatic, and skin cancer. The variants identi-
fied were also distributed over a broad range of tumor(tissue) types: gliomas/glioblastomas, adenomas (colorectal),
lymphomas (non-Hodgkin’s), adenocarcinomas (lung,
gastric), melanomas, leukemias, and carcinomas (thy-
roid, basal cell, renal cell, esophageal, cervical, nasopha-
ryngeal, hepatocellular). The majority of the cancer
predisposition variants related to lung, colorectal, and
breast cancer (Fig. 4).
Table 1 The DM (disease-causing mutations) and DM? (putative disease-causing mutations but where there is some residual doubt
as to pathological significance) mutations identified in each family
Cancer type HGMD tag
Family A, annotated variants
dbsnp.129:rs56250729 Prostate cancer DM?
dbsnp.125:rs28756990 Endometrial cancer DM?
dbsnp.131:rs77067228 Cancer DM?
dbsnp.89:rs1799966 Breast and/or ovarian cancer DM/DM?
dbsnp.113:rs4986852 Breast cancer DM?
COSMIC:mut:148278;dbsnp.86:rs799917 Breast and/or ovarian cancer DM
dbsnp.89:rs1799950 Breast cancer DM
dbsnp.98:rs2229995 Adenomatous polyposis coli DM?
dbsnp.127:rs41545019 Colorectal cancer DM?
dbsnp.98:rs1805324 Colorectal cancer, non-polyposis DM?
dbsnp.129:rs61753720 Acute lymphoblastic leukemia DM
Family B, Annotated variants
dbsnp.126:rs33927012 Medullary thyroid carcinoma DM?
dbsnp.98:rs2229992 Adenomatous polyposis coli DM
dbsnp.76:rs41115 Adenomatous polyposis coli DM
dbsnp.79:rs169547 Breast cancer DM?
dbsnp.103:rs3092994 Breast cancer DM?
dbsnp.89:rs1799966 Breast cancer DM
dbsnp.86:rs1060915 Breast cancer DM
dbsnp.125:rs28897689 Breast and/or ovarian cancer DM
COSMIC:mut:148278;dbsnp.86:rs799917 Breast and/or ovarian cancer DM
dbsnp.60:rs16940 Breast cancer DM
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ther dbSNP or the 1000 Genomes Project/exome variant
server data were considered to be of prime interest;MSH2
c.2732T>A (p.Leu911Arg), BRCA1 c.2955delC, and
KMT2D c.13895delC and c.1940C>A variants (Additional
file 1: Table S1). The MSH2 c.2732T>A (p. Leu911Arg)
variant is novel as it is not present in HGMD. The
KMT2D c.13895delC and c.1940C>A variants are reported
herein as incidental findings. All the putative cancer-
associated mutations were also considered in terms of
assessing personalized cancer-susceptibility risk from gen-
ome sequence data.
It became evident that, among the 571 cancer risk-
associated variants identified, some were common be-
tween the two families considered, whereas others were
unique (Fig. 5). In particular, 609 variants were found in
both families, while 74 variants were unique to family A
and 551 variants were only found in family B. Comment-
ing on the unique variants obtained, family B comes
from northern Greece, a quite distant location from
Athens (300.13 km) where family A is from, implying a
different genetic origin.In silico and replication analyses
To ascertain whether the variants of interest (MSH2
c.2732T>A (p. L911R) and BRCA1 c.2955delC) have
functional significance, in silico analysis was performed
using the SIFT and PROVEAN algorithms [21, 22]. As
depicted in Table 2, SIFT analysis yielded a p.L911R sub-
stitution (MSH2 c.2732T>A) which was predicted to be
“deleterious” to protein function with a score equal to or
less than 0.05, implying that this could be a pathologic-
ally relevant variant. Moreover, PROVEAN’s scoring
scheme has been shown to perform well in separating
disease-associated variants from common polymor-
phisms [25]. It is thought that non-synonymous SNPs
exhibiting a deleterious effect on function may have be-
come established, being potentially beneficial under
some historical conditions, although today they may
only be found at low frequency [26]. Using a polymerase
chain reaction (PCR)-based conventional Sanger rese-
quencing approach, MSH2 c.2732T>A (p. L911R) was
subsequently investigated in a pool of ethnically matched
control samples and determined to be an infrequent
variant in agreement with PROVEAN’s scoring scheme.
Fig. 4 Variants identified by cancer type in all 11 genomes from the two families under study
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firstly by querying a functional effect and then by proceed-
ing with cancer driver analyses: a general analysis and sub-
sequently a targeted one, choosing “colon” as the tissue
type of interest, on the basis of the findings depicted in
Table 1 regarding MSH2, as well as literature-derived evi-
dence supporting its association with microsatellite in-
stability and hereditary non-polyposis colorectal cancer.
According to the functional analysis outcome, MSH2Fig. 5 Variants identified per family in all 11 genomes from the two familie
disease-causing mutations but where there is some residual doubt as to pa
of prime interest, MSH2 c.2732T>A and BRCA1 c.2955delC, are shownc.2732T>A (p.L911R) and BRCA1 c.2955delC were obse-
rved in various cancer types in COSMIC (grouped by pri-
mary site). Cancer driver gene hits (tumor suppressor genes),
according to Vogelstein and coworkers [27], were also
obtained for BRCA1 c.2955delC and MSH2 c.2732T>A
(p.L911R). Notably, the frameshift variant of BRCA1
was accompanied by a TARGET (Tumor Alterations
Relevant for GEnomics-driven Therapy) drug association hit
(http://www.broadinstitute.org/cancer/cga/target). TARGETs under study. The DM (disease-causing mutations) and DM? (putative
thological significance) mutations identified as well as our two variants
Table 2 SIFT PROVEAN analysis outcome of the two variants of prime interest identified in the 11 family members
HUGO gene
symbol
Chromosome HGVS description
of variant
HGMD
tag
Aminoacid
position
Reference
residue
Alternative
residue
Variation type PROVEAN prediction SIFT prediction
Score Prediction Score Prediction
MSH2 2 c.2732T>A NA 911 L Q Single AA
Change
−4.14 Deleterious 0.001 Damaging
BRCA1 17 c.2955delC DM 986 Frameshift NA NA NA NA
Source: PROVEAN v1.1.3 (PROVEAN human genome variants tool, http://provean.jcvi.org/genome_submit_2.php?species=human).PROVEAN was developed in order to
predict whether a given protein sequence variation (single or multiple amino acid substitutions, micro-insertions, micro-deletions) affects protein function. To achieve this,
PROVEAN introduces a delta alignment score based on the reference and variant versions of a protein query sequence with respect to sequence homologs (NCBI NR
protein database through BLAST, http://www.ncbi.nlm.nih.gov/). The default score threshold was set at −2.5 for binary classification (deleterious<−2.5 vs.
neutral>−2.5). Similarly (through PSI-BLAST, http://blast.ncbi.nlm.nih.gov/Blast.cgi?CMD=Web&PAGE=Proteins&PROGRAM=blastp&RUN_PSIBLAST=on), SIFT
(http://sift.jcvi.org/) may be applied to naturally occurring non-synonymous polymorphisms. SIFT score ranges from 0 to 1. A SIFT score of ≤0.05 corresponds to
a “damaging” prediction, whereas a SIFT score >0.05 predicts that the variant is likely to be “tolerated”
NA not available (where the precomputed score was not available in the database, the precomputed homologous protein identifiers for the query protein were
retrieved in order to bypass the BLAST search and clustering, and the score was computed based on the homologs)
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clinical action (prediction of therapy response/ resistance,
prognosis, diagnosis).
Discussion
The etiology of cancer is highly complex, being charac-
terized by a strong genetic component (a large number
of somatic as well as germline variants have been associ-
ated with different cancer types), while multiple environ-
mental factors contribute to disease susceptibility. In
1974, Anderson stated that the two- to threefold excess
observed in first-degree relatives of cancer patients is
not indicative of strong genetic effects. They are more
suggestive of the involvement of many genes with small
effects acting in concert with environmental or nonge-
netic factors with larger and more important effects
[28]. Although according to Peto (1980) this was a statis-
tical fallacy [29], it seems that the overall statement is
correct since current epidemiological evidence is sup-
ported by the discovery of low-penetrance genes that
predispose to the majority of cancer types. Under the
polygenic model, a large number of alleles each confer-
ring a small genotypic risk (perhaps a relative risk ofTable 3 CRAVAT functional analysis outcome of the two variants of
HUGO gene
symbol
HGVS description
of variant
HGMD tag Sequence ontology Driver
genes
MSH2 c.2732T>A NA Missense variant TSG
BRCA1 c.2955delC DM Frameshift deletion TSG
Source: CRAVAT tool. In the case of MSH2, cancer driver analyses were also perform
obtained (a driver score close to zero means an increased probability of the mutati
TSG tumor suppressor gene, NA not available1.5–2.0) combine additively or multiplicatively to confer
a range of susceptibilities in the general population [30].
Hence, individuals are at elevated risk in the presence of
the combined effects of several susceptibility alleles. This
implies that unless a large number of the relevant alleles
have been identified for a susceptible group, this group
cannot be targeted for early screening or prophylactic
therapy. Reduced (or incomplete) penetrance may be
also of importance, in an attempt to understand why
healthy individuals can harbor several potentially disad-
vantageous variants in their genomes without suffering
any obvious ill effects. Next-generation sequencing of
entire exomes or genomes of apparently normal healthy
individuals from the general population supports the
view that reduced penetrance is actually a widespread
phenomenon in human genetics [31]. We believe that
large-scale sequencing and genotyping studies of appar-
ently healthy individuals could provide a powerful new
approach to understanding the penetrance of patho-
logical mutations/genotypes.
The advent of next-generation sequencing has pro-
vided unprecedented opportunities to decipher the can-
cer genome and to delineate the molecular etiologyprime interest identified in the 11 family members
Target Occurrences in COSMIC by primary sites (gene mutated)
NA Cervix(1), large intestine (106), autonomic ganglia
(2), central nervous system (2), liver(1), small intestine
(1), haematopoietic and lymphoid tissue (7),
endometrium (18), urinary tract (1), lung (14), breast
(7), skin (4), stomach (1), esophagus (1), ovary (4), NS
(2), prostate (2), kidney (6), pancreas (1)
PARP inhibitor Cervix (1), large intestine (66), stomach (8), central
nervous system (2), pancreas (1), meninges (1),
haematopoietic and lymphoid tissue (3), endometrium
(23), urinary tract (5), lung (42), liver (5), skin (6),
oesophagus (4), ovary (39), NS (2); prostate (2), kidney
(5), breast (33)
ed, selecting “colon” as the tissue type of interest. A driver score of 0.27 was
on being a cancer driver)
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ous applications of next-generation sequencing in the
elucidation of the molecular basis of rare diseases [23]
and pharmacogenomics [32]. Herein, we pursued a next-
generation sequencing-based family genomics approach
in 11 members of two families of Greek descent in order
to identify genomic variants that might predispose fam-
ily members to cancer. None of the individuals tested
had a family history of cancer (germline genomic vari-
ants would not be anticipated), and hence, we aimed to
identify genomic variants, particularly novel variants,
that might predispose currently asymptomatic individ-
uals to various types of cancer.
A total of 571 variants previously shown to be associ-
ated with cancer predisposition were identified. We
assessed both non-synonymous and synonymous varia-
tions, since the latter can impact the mRNA phenotype
(whether via transcription, splicing, mRNA transport or
translation) thereby rendering the synonymous mutation
non-silent [33]. In a recent study that focused on germ-
line mutations in cancer-susceptibility genes, the authors
identified non-synonymous genomic variations in 158
genes causally implicated in carcinogenesis, using high-
quality whole genome sequences from an ancestrally
diverse cohort of 681 healthy individuals, none of whom
were first-degree relatives [34]. As in our study, all indi-
viduals were found to carry multiple variants with the
potential to impact cancer-susceptibility. Bodian and co-
workers, however, focused on the detailed analysis of a
selected subset of five clinically important cancer genes
(BRCA1, BRCA2, KRAS, TP53, and PTEN), highlighting
differences between germline variants and reported som-
atic mutations, reporting on their allele frequencies by
ancestry. Differences between ancestry groups (African,
African-European, Central Asian, East Asian, European,
Hispanic, others) were also reflected in the number of
cancer-gene variants as well as the number of deleteri-
ous variants per individual. In the case of TP53
c.215C>G (p.P72R), BRCA1 c.2612C>T (p.P871L),
ERBB2 c.3508C>G (p. P1170A), and FLT3 c.680C>T
(p.T227M), the minor allele in one population was
shown to be the major allele in another.
Our study revealed four variants—namely, BRCA1
c.2955delC, MSH2 c.2732T>A (p.L911R), and KMT2D
c.13895delC and c.1940C>A—that have not been anno-
tated in either dbSNP or the 1000 Genomes Project/ex-
ome variant server data. It should be noted that there is
no HGMD entry for MSH2 c.2732T>A (p.L911R), and
hence, it may be considered to be novel. Inherited muta-
tions in BRCA1 are well known to confer an increased
lifetime risk of developing breast or ovarian cancer.
BRCA1 is a tumor suppressor gene that is involved in
the maintenance of genome stability (homologous re-
combination pathway for double-strand DNA repair)and hence is of paramount importance in hereditary breast
and ovarian cancers. However, the identification of an evi-
dently detrimental BRCA1 variant in a healthy individual is
not unlikely [35]. This may raise awareness regarding the
use of next-generation sequencing in oncology.
MSH2 c.2732T>A (p.L911R) was predicted by PRO-
VEAN to be “deleterious” to protein function, implying
that this is a case of a disease-associated variant (amino
acid variant that deviates from the frequently occurring
residue) and was assigned a driver mutation score close
to zero (a driver score close to zero implies increased
likelihood of the mutation being a cancer driver) for
colon cancer (by CRAVAT). Using a PCR-based conven-
tional Sanger resequencing approach, this variant was
verified as a non-frequent one in agreement with PRO-
VEAN’s scoring scheme, separating disease-associated
variants from common polymorphisms [25]. The DNA
mismatch repair protein Msh2 (also known as MutS
protein homolog 2, MSH2) is encoded by the MSH2
gene (tumor suppressor gene), which is located on
chromosome 2. Mutations in the MSH2 gene are associ-
ated with microsatellite instability and cancer (hereditary
non-polyposis colorectal cancer (HNPCC)). MSH2, as a
heterodimer with MSH6, forms the human MutSα mis-
match repair complex. MSH3 is also a dimerization part-
ner of MSH2 towards the formation of the MutSβ DNA
repair complex. MSH2 participates in several DNA re-
pair processes, such as transcription-coupled repair [36],
homologous recombination [37] as well as base excision
repair [38]. The amino acid change consequent to the
identified missense variant is located within the protein
domain that serves to allow MSH2 to interact with
MSH6/MSH3 [38]. Although the crystal structure of an
MSH2/MSH6 heterodimer in complex with a DNA frag-
ment has been solved [39, 40], the region containing the
p.L911 residue was not resolvable. For this reason, we
were unable to visualize the effect that the p.L911R
might have on the protein.
KMT2D c.13895delC is a mutation, which has previ-
ously been associated with Kabuki (Niikawa-Kuroki)
syndrome (autosomal dominant) with a particularly se-
vere congenital phenotype: left-sided cardiac abnormal-
ities, facial dysmorphisms, skeletal, renal and anorectal
malformations, and hypertricosis [41, 42]. Interestingly,
this syndrome has also been associated with cancer pre-
disposition in children. The KMT2D protein encoded by
this gene is a histone methyltransferase that methylates
the Lys-4 position of histone H3 [43]. This notwithstand-
ing, both KMT2D variants obtained herein (c.13895delC
and c.1940C>A) are reported as incidental findings. There
is currently an ongoing debate about reporting incidental
findings in the context of genomic testing. American Col-
lege of Medical Genetics and Genomics (ACMG) recom-
mendations have been established and approximately 1 %
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incidental variant that falls within the ACMG recommen-
dations [44]. Although the aforementioned KMT2D vari-
ants were not given in the ACMG list, we chose to report
and note them as incidental findings that could require
further evaluation.
Our study has a number of limitations. Firstly, func-
tional analysis of the BRCA1 c.2955delC and MSH2
c.2732T>A (p.L911R) variants was not performed. Sec-
ondly, although the SIFT-based in silico analysis pro-
vides an assessment of the likely pathogenicity of these
novel variants, it cannot fully replace functional assays.
Furthermore, our study considered only those genomic
variants previously associated with cancer predisposition
and that had been logged in HGMD Professional at the
time of our analysis. Since this resource is frequently up-
dated, the bioinformatics analysis of these genomes
should be replicated periodically to exploit any new vari-
ants reported therein. Looking to the future, whole gen-
ome sequencing should ideally be performed once, e.g.,
at birth, with data analysis being frequently replicated
thereafter in order to exploit the wealth of genomic
knowledge that is continually becoming available. Lastly,
family history is of central importance in medical/clinical
practice, since it reflects both genetic and environmental
exposures within families. Herein, none of the individ-
uals reported had a family history of cancer (germline
genomic variants would not be anticipated), rendering it
highly questionable as to whether they would meet the
normal criteria for genetic counseling. Incidental find-
ings and reduced (incomplete) penetrance in cancer
complicate decision-making even further. Nowadays,
genomic data are hardly integrated in medical decision-
making in cancer, given its complexity and as educa-
tional initiatives and support from specialists are also
lacking [45]. In this context, a community knowledge
base has been proposed by Good and coworkers (2014)
to facilitate collaborative contributions and open discus-
sions on genomic events [46].
In relation to the diagnosis and prognosis of cancer
patients, data interpretation requires an understanding
of the variation in cancer risk-associated genes in
healthy individuals. This knowledge is still largely lack-
ing. Herein, we followed a family-based genomics ap-
proach in healthy individuals to assess cancer risk via
the identification of genomic variants, particularly novel
ones that might predispose to various types of cancer. A
crude assessment of the potential extent of the genome-
wide cancer-susceptibility burden in normal healthy in-
dividuals was also an objective of this study, taking into
account all the (putative) risk-associated mutations ob-
tained. As whole genome and/or whole exome sequen-
cing approaches begin to be recruited into clinical care,
our understanding of detected sequence variations ondiagnosis (and prognosis) needs to become more readily
accessible to the clinician. This is not a trivial undertaking,
especially as the polygenic model proposes that an individ-
ual’s cancer risk is the net outcome of the presence of mul-
tiple variants and environmental factors [47]. The use of
next-generation sequencing is expected to play a crucial
role in delineating an individual’s variome as well as pro-
viding the means to identify novel variants to improve
therapeutic modalities. Signature-based drug-repositioning
methods are also known to make use of gene signatures to
uncover unknown mechanisms of action of molecules
and drugs by coupling the significantly changed genes
to computational approaches [48]. As whole genome se-
quencing services become more accurate in delivering
clinical-grade genome sequences and whole genome se-
quencing costs continue to decline, it is expected that this
approach will gradually assume an integral role in gen-
omic medicine. The next-generation sequencing-based
family genomics approach employed here could be readily
replicated for other types of disorders to identify causative
variants and/or in the context of signature-based drug-
repositioning methods.
Additional file
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categorized by genome/family member on the basis of the text mining
terms used.
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